Hypophosphatemic effect of niacin in patients without renal failure: A randomized trial

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 4, 2010, Pages 582-589

  MacCubbin, Darbie ^a   Tipping, Diane ^a   Kuznetsova, Olga ^a   Hanlon, William A ^a   Bostom, Andrew G ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PHOSPHORUS; PLACEBO;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CALCIUM; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; INDOLES; KIDNEY DISEASES; MALE; MIDDLE AGED; NIACIN; PHOSPHORUS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77950959254     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07341009     Document Type: Article

References (50)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1: 607-617, 1998 (Pubitemid 28158000)
2. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO4, Ca X PO4 product, and parathyroid hormone with cardiac mortality risk in hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
3. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005 (Pubitemid 41725150)
4. Menon V, Greene T, Pereira AA, Wang X, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ: Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 46: 455-463, 2005 (Pubitemid 41208181)
5. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 70: 351-357, 2006 (Pubitemid 44086585)
6. Levin A, Djurdjev O, Beaulieu M, Er L: Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 52: 661-671, 2008
7. Onufrak SJ, Bellasi A, Shaw LJ, Herzog CA, Cardarelli F, Wilson PW, Vaccarino V, Raggi P: Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 199: 424-431, 2008
8. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA: Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 20: 397-404, 2009
9. Ix JH, De Boer IH, Peralta CA, Adeney KL, Duprez DA, Jenny NS, Siscovick DS, Kestenbaum BR: Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 4: 609-615, 2009
10. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB, Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167: 879-885, 2007 (Pubitemid 46762749)
11. Foley RN, Collins AJ, Ishani A, Kalra PA: Calcium-phosphate levels and cardiovascular disease in the community-dwelling adults: The Atherosclerotic Risk in Communities (ARIC) Study. Am Heart J 156: 556-563, 2008
12. Onufrak SJ, Bellasi A, Cardarelli F, Vaccarino V, Muntner P, Shaw LJ, Raggi P: Investigation of gender heterogeneity in the association of serum phosphorus with incident coronary artery disease and all-cause mortality. Am J Epidemiol 169: 67-77, 2009
13. Narang R, Ridout D, Nonis C, Kooner JS: Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol 60: 73-79, 1997 (Pubitemid 27288259)
14. Rasouli M, Mohseni-Kiasari A: Serum calcium and phosphorus associate with the occurrence and severity of angio-graphically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins. Clin Chem Lab Med 44: 43-50, 2006 (Pubitemid 43010644)
15. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633, 2005 (Pubitemid 41532599)
16. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002 (Pubitemid 34754068)
17. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824, 2005 (Pubitemid 43169927)
18. Coladonato JA: Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 16[Suppl 2]: S107-S114, 2005
19. Joy MS, Finn WF: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42: 96-107, 2003
20. Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, De Broe ME, D'Haese PC: Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 15: 2219-2228, 2004 (Pubitemid 39031361)
21. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65: 1914-1926. 2004 (Pubitemid 38591044)
22. Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey NM, Drueke TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67: 1062-1069, 2005 (Pubitemid 41623331)
23. Pennell P, Leclercq B, Delahunty MI, Walters BA: The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease. Clin Nephrol 66: 336-347, 2006 (Pubitemid 44718145)
24. Shimoda K, Akiba T, Matsushima T, Rai T, Abe K, Hoshino M: Niceritrol decreases serum phosphate levels in chronic hemodialysis patients [in Japanese]. Nippon Jinzo Gakkai Shi 40: 1-7, 1998 (Pubitemid 28103325)
25. Takahashi Y, Tanaka, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H: Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099-1104, 2004 (Pubitemid 38251086)
26. Sampathkumar K, Selvam M, Sooraj Y, Gowthaman S, Ajeshkumar R: Extended release nicotinic acid is a novel agent for phosphate control in dialysis. Int Urol Nephrol 38: 171-174, 2006 (Pubitemid 43299838)
27. Müller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, Kettritz R: Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2: 1249-1254, 2007
28. Restrepo Valencia CA, Cruz J: Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphos-phatemia [in Spanish]. Nefrologia 28: 61-66, 2008
29. Cheng SC, Young DO: A Randomized, double blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3: 1131-1138, 2008
30. Sampathkumar K: Niacin and analogs for phosphate control in dialysis: Perspective from a developing country. Int Urol Nephrol 41: 813-819, 2009
31. Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47: 1097-1104, 1998 (Pubitemid 28428015)
32. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J: Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Am J Cardiol 82: 74U-81U, discussion 85U-86U, 1998
33. Guyton JR, Blazing Ma, Hagar J, Kashyap ML, Knopp RH, McKenney JM, Nash DT, Nash SD: Extended-release niacin vs. gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med 160: 1177-1184, 2000 (Pubitemid 30227029)
34. Maccubbin D, Bays HE, Olson G, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, McCrary Sisk C, Pasternak RC, Paolini JF: Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidaemia. Int J Clin Pract 62: 1959-1970, 2008. ClinicalTrials.gov registration, 〈http://ClinicalTrials.gov〉 number: NCT00269204
35. Debiec H, Lorenc R: Identification of Na+, Pi-binding protein in kidney and intestinal brush-border membranes. Biochem J 255: 185-191, 1988
36. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, Kuboyama N, Suzuki T, Akiba T, Miyamoto K, Takeda E: Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14: 1195-1201, 1999 (Pubitemid 29209307)
37. Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T: Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 14: 610-614, 1999 (Pubitemid 29105986)
38. Eto N, Miyata Y, Ohno H, Yamashita T: Nicotinamide prevents the development of hyperphosphatemia by suppressing the intestinal sodium dependent phosphate transporter in rats with adenine induced renal failure. Nephrol Dial Transplant 20: 1378-1384, 2005 (Pubitemid 41430611)
39. Sabbagh Y, O'Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C, Schiavi SC. Intestinal Npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20: 2348-2358. 2009
40. Portale AA: Blood calcium, phosphorus, and magnesium. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edited by Favus MJ, Philadelphia, Lippincott Williams & Wilkins, 1999, pp 115-118
41. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
42. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 76[Suppl 113]: S121-S130, 2009
43. Chonchol M, Dale R, Schrier RW, Estacio R: Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med 122: 380-386, 2009
44. Block GA, Persky MS, Ketteler M, Kestenbaum B, Thadhani R, Kooienga L, Spiegel D, Asplin J, Ehrlich J, Dennis V, Nissenson A, Chertow GM, Wheeler DC: A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: A new paradigm for clinical outcomes studies in nephrology. Hemodial Int 13: 360-362, 2009
45. Isakova T, Gutiérrez OM, Wolf M: A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 76: 705-711, 2009
46. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W: Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: A randomized trial. Clin J Am Soc Nephrol 4: 178-185, 2009
47. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol November 12, 2009 [epub ahead of print]
48. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R: Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 4: 1089-1096. 2009
49. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 8: 1245-1255, 1986
50. Coca SG, Krumholz HM, Garg AX, Parikh CR: Under-representation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296: 1377-1384. 2006 (Pubitemid 44427424)